Advertisement
Advertisement

Research Alert: Study Casts Doubt on "Shock and Kill" Cure Strategy

Medical News

Bristol-Myers, J&J Team Up Against Hepatitis C

December 6, 2011

Bristol-Myers Squibb Co. and Johnson & Johnson said Friday they will work together to develop experimental treatments for hepatitis C virus. BMS said its drugs daclatasir (BMS-790052) and its NS5A replication complex inhibitor will be tested in combination with the NS3 protease inhibitor (TMC435) under development by J&J's Tibotec unit. Beginning in the first half of 2012, the medicines, which seek to block different proteins than those usually targeted by HCV treatments, will be tested in various combinations among patients with genotype 1, the most common and hard-to-treat HCV strain. Several companies are working to develop HCV treatments that do not include interferon, whose flu-like side effects cause many patients to avoid or discontinue treatment.

Back to other news for December 2011

Adapted from:
Reuters
12.02.2011; Ransdell Pierson; Bill Berkrot




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement